Christopher R Cabanski

8PUBLICATIONS
149CO-AUTHORS
Innate immunityCancer therapy (excl. chemotherapy and radiation therapy)Gene and molecular therapyMolecular targetsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Aug 05, 2026
Deep learning representations of human Immune Health for precision immunology.

|Jan 30, 2026
Clinical and translational results from a phase 1 trial of gemcitabine/nab-paclitaxel with nivolumab/ipilimumab or hydroxychloroquine/ipilimumab in untreated metastatic pancreatic adenocarcinoma.

Eileen M O'Reilly, Christopher R Cabanski, Jaclyn P Lyman

|Jan 07, 2026
IL10R Inhibition Induces Neutrophil Tumoricidal Activity.

Danny N Khalil, Ricardo Gomez, Amit Regev

|Dec 02, 2025
Enabling access to genetically modified cell therapies through flexible approaches to manufacturing and cost recovery.

Mark D Stewart, Christopher R Cabanski, Jeff D Allen

|Feb 18, 2025
Clinical and Translational Results from PORTER, a Multicohort Phase I Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate Cancer.

Matthew D Galsky, Karen A Autio, Christopher R Cabanski

|Aug 27, 2024
Immunologic signatures of response and resistance to nivolumab with ipilimumab in advanced metastatic cancer.

Apostolia M Tsimberidou, Farah A Alayli, Kwame Okrah

Pageof 2

Frequent Collaborators

4 joint publications

Diane M Da Silva

3 joint publications

Mark H O'Hara

3 joint publications

Richard O Chen

3 joint publications

Theresa M LaVallee